Astellas Venture Management Llc investment portfolio

Crescendo Biologics Limited is a private, clinical‑stage immuno‑oncology company that develops novel, targeted T‑cell‑enhancing Humabody® therapeutics, including pipeline candidates such as the CD137 × PSMA Humabody CB307 for solid tumours and other multi‑specific Humabodies for cancer and inflammatory diseases. Its products are aimed at activating tumour‑specific T cells within the tumour microenvironment and are being advanced through clinical trials and collaborations with partners such as Takeda, BioNTech and Zai Lab.

Mogrify Limited develops a proprietary big‑data and computational platform (Mogrify®/EPIMOGRIFY®) that predicts and implements the transcriptomic switches required to directly reprogram cells. Its technology is aimed at biotech and pharmaceutical companies developing ex vivo and in vivo cell‑therapy products.